MedTrace Logo

A Food-Effect Study of CX11 in Healthy Participants

NCT07349381 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2026-03-27

No results posted yet for this study

Summary

This study is to evaluate the food effect (FE) on the PK of 200 mg CX11 in healthy participants

Conditions

Interventions

DRUG

CX11 (VCT220)

CX11 (VCT220) administered orally to participants who are in fasted/fed state in the first 6 consecutive days, and in fed/fasted state on the 7th day

Sponsors & Collaborators

  • Corxel Pharmaceuticals

    collaborator INDUSTRY

  • Vincentage Pharma Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-03-04
Primary Completion
2026-06-30
Completion
2026-09-30
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07349381 on ClinicalTrials.gov